Preclinical Imaging (In-VIVO) Market is expected to reach 1401.86 million by 2027 at CAGR of 4.92%. Preclinical imaging is medical process of visualization of living animals for purpose of research, such as new medical procedure and drug development . In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes.
In application aspect, vivo imaging is increasingly deployed across the drug development process, with applicability in target identification, compound optimisation and pre-Phase I studies. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. The key diseases/therapeutic areas targeted with in vivo preclinical imaging by survey respondents were oncology/cancer (70% targeting). This was followed by inflammatory disease/autoimmune (36% targeting), neurology / CNS / neurodegeneration/ pain (32% targeting) and then cardiovascular (25% targeting)
Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. The most suitable modalities for small-animal in vivo imaging applications are based on nuclear medicine techniques (essentially, positron emission tomography [PET] and single photon emission computed tomography [SPECT]), optical imaging (OI), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy imaging (MRSI), and ultrasound
Geographically, Preclinical Imaging (In-VIVO) Market categorised in North America, Europe, China, Japan, South East Asia, India and Rest of World. North America holds the highest sale volume of market. Increased in Pharmaceutical research, New development in biotechnology, government support for various research work and advancement in technology are the prime factor driving the Preclinical Imaging (In-VIVO) Market globally. Europe and Asia –Pacific market is expected to grow at higher CAGR in forecasted years. African market expected to grow at lower rate while Middle East and South American market is expected to show constant growth rate.
Preclinical Imaging (In-VIVO) Market: Techniques Type
- MRI (Magnetic Resonance Imaging)
- PET (Positron Emission Tomography)
- SPECT (Single Photon Emission Computed Tomography)
- Micro-CT (Micro Computed Tomography)
- Optical imaging and Magnetic particle (MPI)
Preclinical Imaging (In-VIVO) Market: Vessel Type
- Oncology
- Neurology
- Cardiology
- Inflammation
- Infectious diseases
- Cancer research
- Functional and Anatomical Neuroimaging
- Orthopedics
- Cardiac imaging
- Stroke models
Preclinical Imaging (In-VIVO) Market : Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Preclinical Imaging (In-VIVO) Market:
- PerkinElmer
- Bruker Corporation
- FUJIFILM Holdings
- Mediso
- MILabs B.V.
- MR Solutions
- Aspect Imaging
- LI-COR Biosciences
- Trifoil Imaging
- Miltenyi Biotec
Geographical analysis of Preclinical Imaging (In-VIVO) Market:
-
North America
- Europe
- France
- Germany
- Spain
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South East Asia
- Latin America
- Middle East and Africa
Preclinical Imaging (In-VIVO) Market Report delivers a comprehensive analysis of the following parameters :
- Market Forecast for 2018-26
- Market growth drivers
- Challenges and Opportunities
- Emerging and Current Market trends
- Market player Capacity, Production, Revenue (Value)
- Supply (Production), Consumption, Export, Import analysis
- End-user/application Analysis
